Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19067148 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL1509061 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL18094067 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL19388647 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL875540 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL19131391 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL15116723 | 0.88 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL20054341 | 0.88 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL15776914 | 0.86 | CNR2 (0.38) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL15776913 | 0.86 | CNR2 (0.38) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211116-A1 | NOVEL HETEROCYCLIC ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-07-19 | — | — | EP | disclosed |
| CN-116096709-A | Novel heterocyclic antibiotics | 豪夫迈·罗氏有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4093734-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| CN-114981259-A | Novel heterocyclic compound | 豪夫迈·罗氏有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170204110-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2017-07-20 | — | — | US | disclosed |
| US-20170204110-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2017-07-20 | — | — | US | disclosed |
| WO-2017117239-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| EP-2618831-B1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2012040167-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | HSD17B10 1161/4885HDAC8 1509/4885SMN1; SMN2 3187/4885 |
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | HSD17B10 1161/4885HDAC8 1509/4885SMN1; SMN2 3187/4885 |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | PREP, PRSS1, PEPD | HSD17B10 1161/4885HDAC8 1509/4885SMN1; SMN2 3187/4885 |
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | HSD17B10 1161/4885HDAC8 1509/4885SMN1; SMN2 3187/4885 |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | HSD17B10 1161/4885HDAC8 1509/4885SMN1; SMN2 3187/4885 |
| US-20170204110-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | HSD17B10 552/4885HDAC8 2213/4885SMN1; SMN2 3096/4885 |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | HSD17B10 1161/4885HDAC8 1509/4885SMN1; SMN2 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.